Muoz-Corcuera
M, Ramrez-Martnez-Acitores L, Lpez-Pintor RM, Casaas-Gil E,
Hernndez-Vallejo G.
Dabigatran:
A new oral anticoa-gulant. Guidelines to follow in oral
surgery procedures. A systematic review of the
literature.
Med
Oral Patol Oral Cir Bucal. 2016 Nov 1;21 (6):e679-88.
doi:10.4317/medoral.21202
http://dx.doi.org/doi:10.4317/medoral.21202
|
1.
Quintero Gonzalez JA. Fifty years of clinical use of warfarin. Invest Clin.
2010;51:269-87. |
|
|
|
|
|
2.
Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T,
et al. Comparison of the cost-effectiveness of new oral anticoagulants for
the prevention of stroke and systemic embolism in atrial fibrillation in a UK
setting. Clin Ther. 2014;36:2015-28. |
|
|
|
|
|
3.
Nishio H, Ieko M, Nakabayashi T. New therapeutic option for
thromboembolism--dabigatran etexilate. Expert Opin Pharmacother.
2008;9:2509-17. |
|
|
|
|
|
4.
Golembiewski JA. Dabigatran: a new oral anticoagulant. J Perianesth Nurs.
2011;26:420-3. |
|
|
|
|
|
5.
Cohen HV, Quek SY, Subramanian G, Abbas A. New antiplatelet and anticoagulant
drugs. Considerations for dental patient management. JNJ Dent Assoc.
2013;84:30-3. |
|
|
|
|
|
6.
Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. American
College of Chest Physicians. Prevention of VTE in nonsurgical patients:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College
of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.
2012;141:e195S-226S. |
|
|
|
|
|
7.
Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al.
Periprocedural bleeding and thromboembolic events with dabigatran compared
with warfarin: results from the Randomized Evaluation of Long-Term
Anticoagulation Therapy (RE-LY) randomized trial. Circulation.
2012;126:343-8. |
|
|
|
|
|
8.
Gmez-Moreno G, Aguilar-Salvatierra A, Martn-Piedra MA, Guardia J,
Calvo-Guirado JL, Cabrera M, et al. Dabigatran and rivaroxaban, new oral
anticoagulants, new approaches in dentistry. J Clin Exp Dent. 2010;2:e1-5. |
|
|
|
|
|
9.
Little JW. New oral anticoagulants: will they replace warfarin? Oral Surg
Oral Med Oral Pathol Oral Radiol. 2012;113:575-80. |
|
|
|
|
|
10.
Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral
anticoagulants and their implications for the management of dental patients.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:431-41. |
|
|
|
|
|
11.
Davis C, Robertson C, Shivakumar S, Lee M. Implications of Dabigatran, a
direct thrombin inhibitor, for oral surgery practice. J Can Dent Assoc.
2013;79:74. |
|
|
|
|
|
12.
Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to
bleeding in patients taking dabigatran. Circulation. 2012;126:2428-32. |
|
|
|
|
|
13.
Van Diermen DE, van der Waal I, Hoogstraten J. Management recommendations for
invasive dental treatment in patients using oral antithrombotic medication,
including novel oral anticoagulants. Oral Surg Oral Med Oral Pathol Oral
Radiol. 2013;116:709-16. |
|
|
|
|
|
14.
Kerr R, Ogden G, Sime G. Anticoagulant guidelines. Br Dent J. 2013;214:430. |
|
|
|
|
|
15.
Romond KK, Miller CS, Henry RG. Dental management considerations for a
patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral
Pathol Oral Radiol. 2013;116:e191-5. |
|
|
|
|
|
16.
Breik O, Cheng A, Sambrook P, Goss A. Protocol in managing oral surgical
patients taking dabigatran. Aust Dent J. 2014;59:296-301. |
|
|
|
|
|
17.
Curtin C, Hayes JM, Hayes J. Dental Implications of new oral anticoagulants
for atrial fibrilacion. Dent Update. 2014;41:526-31. |
|
|
|
|
|
18.
Sivolella S, De Biagi M, Brunello G, Berengo M, Pengo V. Managing
dentoalveolar surgical procedures in patients taking new oral anticoagulants.
Odontology. 2015;103:258-63. |
|
|
|
|
|
19.
van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al.
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor:
interpretation of coagulation assays and reversal of anticoagulant activity.
Thromb Haemost. 2010;103:1116-27. |
|
|
|
|
|
20.
Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of
efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban,
apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol.
2012;110:453-60. |
|
|
|
|
|
21.
Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A
specific antidote for dabigatran: functional and structural characterization.
Blood. 2013;121:3554-62. |
|
|
|
|